Preclinical Rationale for PI3K/Akt/mTOR Pathway Inhibitors as Therapy for Epidermal Growth Factor Receptor Inhibitor-Resistant Non–Small-Cell Lung Cancer

This publication has 75 references indexed in Scilit:

• Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
  Nature Reviews Cancer, 2010
• Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer
  Cancer, 2010
• Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
  Cancer Cell, 2010
• Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
  Nature, 2009
• Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
  New England Journal of Medicine, 2009
• Targeting the phosphoinositide 3-kinase pathway in cancer
  Nature Reviews Drug Discovery, 2009
• BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
  Oncogene, 2008
• Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
  New England Journal of Medicine, 2005
• ERBB receptors and cancer: the complexity of targeted inhibitors
  Nature Reviews Cancer, 2005
• Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
  New England Journal of Medicine, 2004